Crohn's & colitis 360 · 2026
Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Han Justin, Puangampai Archariya, Man Bernice, Kandah Huda-Marie, Rubin David T, Choi David K
Аннотация
BACKGROUND: An evolving strategy to enhance quality of life and remission rates in inflammatory bowel disease (IBD) is the treat-to-target approach. This approach offers a structured algorithm for therapeutic interventions, yet its implementation faces challenges, such as administrative burden and limited resources. This study elucidates the pharmacist's role in the treat-to-target approach.
METHODS: Retrospective chart review was conducted from August 7 to December 15, 2023. Patients ≥ 18 years of age, diagnosed with IBD, initiated on upadacitinib or risankizumab were included. "Treat-to-target" was defined as serial communication and monitoring of symptoms, clinical response, and laboratory values at predefined time points after starting therapy. A pharmacist-led follow-up protocol was conducted by an embedded IBD clinical pharmacist who assessed successful therapy initiation, medication adherence, steroid use, adverse effects, clinical disease activity, need for clinic visits, and lab monitoring at 2, 4, 8, 12 weeks, 6 months, and 12 months after therapy initiation.
RESULTS: It was found that 227 patients initiated upadacitinib, and 210 initiated risankizumab. The overall success rate in reaching patients for through the pharmacist-directed follow-up protocol was 84%. The IBD Pharmacist made 3512 interventions, the most common being therapy continuation and lab monitoring recommendations. Therapy discontinuations were observed, particularly between 12 weeks and 6 months post-initiation.
CONCLUSIONS: We demonstrate a high participation rate to a pharmacist-led follow-up and monitoring protocol for patients receiving upadacitinib and risankizumab therapy. These findings underscore the importance of pharmacist-led interventions in ensuring continuity of care and tracking patient progress with IBD therapies, which are key elements of a successful treat-to-target strategy.
METHODS: Retrospective chart review was conducted from August 7 to December 15, 2023. Patients ≥ 18 years of age, diagnosed with IBD, initiated on upadacitinib or risankizumab were included. "Treat-to-target" was defined as serial communication and monitoring of symptoms, clinical response, and laboratory values at predefined time points after starting therapy. A pharmacist-led follow-up protocol was conducted by an embedded IBD clinical pharmacist who assessed successful therapy initiation, medication adherence, steroid use, adverse effects, clinical disease activity, need for clinic visits, and lab monitoring at 2, 4, 8, 12 weeks, 6 months, and 12 months after therapy initiation.
RESULTS: It was found that 227 patients initiated upadacitinib, and 210 initiated risankizumab. The overall success rate in reaching patients for through the pharmacist-directed follow-up protocol was 84%. The IBD Pharmacist made 3512 interventions, the most common being therapy continuation and lab monitoring recommendations. Therapy discontinuations were observed, particularly between 12 weeks and 6 months post-initiation.
CONCLUSIONS: We demonstrate a high participation rate to a pharmacist-led follow-up and monitoring protocol for patients receiving upadacitinib and risankizumab therapy. These findings underscore the importance of pharmacist-led interventions in ensuring continuity of care and tracking patient progress with IBD therapies, which are key elements of a successful treat-to-target strategy.